SVB Securities analyst Andrew Berens upgraded Incyte to Market Perform from Underperform with a $61 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INCY:
- BofA sees minimal near-term impact on Incyte from ruxolitinib ER CRL
- Incyte provides regulatory update on Ruxolitinib extended relief
- MacroGenics to receive $15M milestone following FDA approval of Zynyz
- Incyte announces FDA accelerated approval of Zynyz
- Incyte announces data from Phase 2b study evaluating Povorcitinib
Questions or Comments about the article? Write to editor@tipranks.com